Wegovy vs Zepbound: Cost and Access Head-to-Head

Efficacy: What the Trials Actually Showed

Comparing these two drugs requires honesty about one limitation: no published head-to-head randomized trial pits Wegovy directly against Zepbound. The efficacy numbers come from separate studies with different patient populations, run at different times.

In the STEP-1 trial (N=1,961), participants receiving semaglutide 2.4 mg once weekly lost a mean of 14.9% of their body weight over 68 weeks, compared with 2.4% in the placebo group [1]. The study enrolled adults with a BMI of 30 or higher (or 27 or higher with at least one weight-related comorbidity) and excluded those with type 2 diabetes. Published in the New England Journal of Medicine in 2021, STEP-1 established the clinical benchmark for GLP-1 receptor agonist monotherapy in obesity [1].

SURMOUNT-1 (N=2,539) tested tirzepatide at three doses: 5 mg, 10 mg, and 15 mg. At the highest dose, participants lost a mean of 20.9% of body weight over 72 weeks versus 3.1% with placebo [2]. The trial also excluded patients with diabetes and used a similar BMI threshold for enrollment. Published in the New England Journal of Medicine in 2022, SURMOUNT-1 reported weight reductions that exceeded those seen in prior GLP-1-only studies [2].

The roughly 6-percentage-point gap between the two top-line results is real. But trial duration differed by four weeks, baseline BMI was slightly higher in SURMOUNT-1 (mean 38.0 vs. 37.9 kg/m²), and tirzepatide is a dual GIP/GLP-1 receptor agonist while semaglutide acts on GLP-1 alone. Cross-trial comparisons carry inherent uncertainty. The only honest conclusion: tirzepatide's weight-loss signal appears larger, and a direct comparison trial would be needed to confirm superiority with statistical rigor.

List Price Comparison

Zepbound carries a lower wholesale acquisition cost (WAC) than Wegovy. That surprises many patients who assume the newer, more effective drug must cost more.

As of early 2026, Wegovy's WAC sits at approximately $1,349 for a 4-week supply of autoinjector pens at the maintenance dose. Zepbound's WAC is approximately $1,059 for a 4-week supply at the maintenance dose. These are list prices, meaning the amount before insurance negotiations, rebates, or savings programs. According to the FDA's approved labeling for Wegovy, the dose-escalation schedule spans 16 weeks before reaching the 2.4 mg maintenance dose, and costs during titration are typically lower per fill [3].

Eli Lilly set Zepbound's launch price below Novo Nordisk's Wegovy price deliberately. The company publicly stated it aimed to improve affordability for anti-obesity medications. But list price is not out-of-pocket cost. What you actually pay depends on insurance tier placement, copay card eligibility, and pharmacy benefit manager (PBM) formulary decisions. A patient with strong commercial coverage might pay $25 per month for either drug. A patient without obesity medication coverage might pay the full list price for both.

Insurance Coverage and Formulary Status

Coverage for anti-obesity medications remains inconsistent across the U.S. insurance market. This is the single biggest factor determining which drug a patient can realistically access.

Medicare Part D does not cover anti-obesity medications under current statute, though legislative proposals to change this (such as the Treat and Reduce Obesity Act) have been reintroduced in multiple congressional sessions. As of 2026, Medicare beneficiaries must pay cash or use manufacturer assistance for either Wegovy or Zepbound when prescribed solely for weight management. The Centers for Medicare & Medicaid Services has clarified that Part D plans may cover these drugs when prescribed for an approved cardiovascular indication, following Wegovy's expanded label for reducing major adverse cardiovascular events in adults with established CVD and obesity or overweight [4].

Commercial insurance presents a mixed picture. Some of the largest employers and health plans have added anti-obesity medication coverage in recent years, driven partly by data from the SELECT trial showing cardiovascular benefit with semaglutide [4]. A 2024 survey by the Employer Health Innovation Roundtable found that roughly 40% of large employers covered at least one GLP-1 for obesity, up from about 25% in 2022.

Formulary placement differs by PBM. Express Scripts, CVS Caremark, and OptumRx have each made distinct decisions about preferred status for Wegovy versus Zepbound. In practice, this means:

• Some plans cover Wegovy but not Zepbound
• Some plans cover Zepbound but not Wegovy
• Some plans cover both but place one on a higher (more expensive) tier
• Some plans cover neither for obesity but cover Ozempic or Mounjaro for type 2 diabetes

Prior authorization is nearly universal. Expect your prescriber to submit documentation of BMI, prior weight-management attempts, and comorbidities. Denial rates remain high. A 2024 analysis of commercial claims data published in Obesity found that approximately 30% of initial prior-authorization requests for GLP-1 receptor agonists were denied, though many were overturned on appeal [5].

Manufacturer Savings Programs

Both Novo Nordisk and Eli Lilly operate copay assistance programs that can sharply reduce out-of-pocket costs for commercially insured patients.

Novo Nordisk's Wegovy Savings Card offers eligible patients a copay as low as $0 for up to 13 fills, with a maximum savings amount per fill. Patients must have commercial insurance. The card does not apply to government-funded plans (Medicare, Medicaid, Tricare). Novo Nordisk has periodically adjusted the terms of this program, so checking the current offer at the time of prescribing is necessary [3].

Eli Lilly launched Zepbound with an aggressive savings strategy. The Zepbound Savings Card provides similar copay reductions for commercially insured patients. Lilly also introduced a direct-to-consumer vial option through LillyDirect at a lower price point than the autoinjector pens, intended to improve access for patients paying cash. The vial program priced single-dose vials starting at $399 per month, though patients must use the vial format, which requires drawing up the dose with a syringe.

For uninsured or cash-pay patients, both drugs are expensive. Neither company's savings card typically applies without commercial insurance. Compounding pharmacies have offered compounded semaglutide and tirzepatide at lower prices, but the FDA has issued warnings about safety and quality concerns with compounded versions, and the regulatory status of compounded GLP-1 products has shifted as drug shortages resolve [6].

Supply and Availability

Both Wegovy and Zepbound have experienced supply disruptions that affected patient access.

Wegovy launched in June 2021 but faced persistent manufacturing constraints. Novo Nordisk restricted new patient starts in 2022 and portions of 2023 to protect supply for existing patients. By late 2024, the company reported improved manufacturing capacity and lifted most starter-dose restrictions [3]. The FDA Drug Shortage Database tracked Wegovy shortages across multiple dose strengths during this period.

Zepbound's launch in late 2023 initially went more smoothly, but intermittent shortages of specific dose strengths (particularly the 2.5 mg and 5 mg starter doses) appeared through 2024 and into 2025. Eli Lilly invested over $9 billion in manufacturing expansion, including new facilities in Indiana, North Carolina, Ireland, and Germany, to increase production capacity for tirzepatide across both the Mounjaro (diabetes) and Zepbound (obesity) brands [7].

From a patient perspective, supply shortages create real clinical problems. Interrupting a GLP-1 agonist mid-titration can cause gastrointestinal side effects when restarting, and extended gaps may lead to weight regain. If you are choosing between the two drugs, ask your pharmacy about current stock levels for all dose strengths in the titration schedule before committing to a 16- to 20-week escalation protocol.

Side Effect Profiles

The tolerability profiles of Wegovy and Zepbound overlap significantly, which makes sense given their shared mechanism of GLP-1 receptor activation.

Gastrointestinal events dominate both profiles. In STEP-1, 44.2% of semaglutide-treated participants reported nausea (vs. 17.4% placebo), 31.1% reported diarrhea (vs. 15.9% placebo), and 24.8% reported vomiting (vs. 6.2% placebo) [1]. In SURMOUNT-1, nausea occurred in 24.6% of the tirzepatide 15 mg group (vs. 9.5% placebo), diarrhea in 21.0% (vs. 9.2% placebo), and vomiting in 12.2% (vs. 2.4% placebo) [2].

These numbers suggest a somewhat lower rate of GI side effects with tirzepatide at its highest dose compared with semaglutide 2.4 mg, though cross-trial comparison caveats apply. Discontinuation rates due to adverse events were 7.0% with semaglutide in STEP-1 [1] and 6.2% with tirzepatide 15 mg in SURMOUNT-1 [2].

Both drugs carry boxed warnings about thyroid C-cell tumors based on rodent data, and both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Cardiovascular Outcomes: An Important Differentiator

One area where Wegovy holds a distinct evidence advantage is cardiovascular outcomes.

The SELECT trial (N=17,604), published in the New England Journal of Medicine in 2023, demonstrated that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (MACE) by 20% compared with placebo in adults with established cardiovascular disease and overweight or obesity, without diabetes [4]. This finding led the FDA to expand Wegovy's indication to include cardiovascular risk reduction in March 2024. Dr. A. Michael Lincoff, the trial's lead investigator, stated: "This is the first time an anti-obesity medication has been shown to reduce cardiovascular events, independent of diabetes status" [4].

Zepbound does not yet have a completed cardiovascular outcomes trial. The SURPASS-CVOT trial (tirzepatide vs. dulaglutide) is studying cardiovascular outcomes in patients with type 2 diabetes, and the SURMOUNT-MMO trial is evaluating tirzepatide for cardiovascular and metabolic endpoints in obesity. Results are expected by 2027. Until those data are published, Wegovy is the only anti-obesity medication with proven cardiovascular benefit. For patients with known cardiovascular disease, this distinction could influence drug selection regardless of cost [8].

The American Heart Association's 2023 Scientific Statement on obesity pharmacotherapy acknowledged semaglutide's cardiovascular evidence and noted the need for similar outcome data with other GLP-1 and dual-agonist therapies before making broad cardiovascular recommendations [9].

How to Choose: A Practical Decision Framework

Choosing between Wegovy and Zepbound involves weighing clinical evidence, insurance realities, and individual health factors. No single answer fits every patient.

If your insurance covers one but not the other: Start there. The best anti-obesity medication is the one you can consistently afford and access. Switching due to cost or formulary changes is common and manageable with prescriber guidance.

If your insurance covers both: Consider the clinical picture. Patients with established cardiovascular disease have stronger evidence supporting Wegovy based on SELECT trial data [4]. Patients prioritizing maximal weight loss may favor Zepbound based on the larger percentage reductions seen in SURMOUNT-1 [2]. Discuss side-effect tolerance with your prescriber, particularly if you have a history of GI sensitivity.

If you are paying cash: Zepbound's lower list price and Lilly's vial program may offer a cost advantage. Compare total titration-to-maintenance costs for a full year, not just the monthly maintenance price.

If you have type 2 diabetes: Neither Wegovy nor Zepbound is indicated for glycemic control. The diabetes-labeled versions (Ozempic for semaglutide, Mounjaro for tirzepatide) may be covered differently by your plan and could alter the cost calculus.

"The decision should be individualized," according to the Endocrine Society's 2024 Clinical Practice Guideline on pharmacological management of obesity. The guideline recommends that clinicians consider "efficacy, safety, tolerability, cost, and patient preference" when selecting among approved anti-obesity medications [10].

State Medicaid and Regional Access Gaps

Medicaid coverage for anti-obesity medications varies state by state, creating geographic disparities in access.

Some states explicitly exclude weight-loss medications from their Medicaid formularies. Others have added coverage for GLP-1 agonists when prescribed for obesity with specific comorbidity documentation. The Kaiser Family Foundation tracks state-level Medicaid drug coverage policies, and as of 2025, fewer than half of state Medicaid programs covered any anti-obesity medication [11].

Patients in states without Medicaid coverage face a particularly steep access barrier, as they are also less likely to have employer-sponsored insurance with obesity drug benefits. Federally Qualified Health Centers (FQHCs) in some regions have negotiated 340B pricing that lowers costs, but availability is inconsistent.

Geographic pharmacy deserts compound the problem. Rural areas with limited pharmacy options may face longer delays when specific dose strengths are in short supply. Mail-order pharmacy programs from both Novo Nordisk and Eli Lilly can partially address this, but require reliable cold-chain shipping for these refrigerated medications.

The Role of Step Therapy and Fail-First Requirements

Many insurers impose step-therapy protocols requiring patients to try and fail cheaper interventions before approving Wegovy or Zepbound. These requirements add months to the process.

Common step-therapy requirements include documented failure of lifestyle modification (diet and exercise) for 3 to 6 months, and in some plans, prior trial of older weight-loss medications such as phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), or orlistat (Xenical/Alli). A few plans require documented failure of one GLP-1 before approving another, meaning a patient might need to try Wegovy first, demonstrate inadequate response or intolerance, and only then gain access to Zepbound.

The American Association of Clinical Endocrinology (AACE) has advocated against restrictive step-therapy requirements for obesity medications, arguing that they delay effective treatment and contradict individualized care [12]. If your plan imposes step therapy, your prescriber can often file a medical exception or peer-to-peer review to expedite access.

Ask your prescriber's office to verify coverage and prior-authorization requirements through a benefits investigation before writing the prescription. Both Novo Nordisk and Eli Lilly offer free benefits-verification services through their patient support programs, and using these services before the first fill can prevent unexpected pharmacy costs.